Home Medical Encyclopedia Disease H Hallervorden-Spatz disease

Hallervorden-Spatz disease

Alternative Names: Pantothenate kinase-associated neurodegeneration

Hallervorden-Spatz disease is a movement disorder that is passed down through families (inherited).

Causes of Hallervorden-Spatz disease

Hallervorden-Spatz disease usually begins in childhood.

Most cases of Hallervorden-Spatz disease are due to a defect in a gene that makes a protein called pantothenate kinase 2. Patients with this genetic defect have a buildup of iron in parts of the brain.

Hallervorden-Spatz disease Symptoms

Tests and Exams

The doctor will perform a physical exam and ask questions about the patient's medical history. It is important to get a complete medical and family history, since the condition can run in families.

A neurological examination will show:

  • Abnormal postures and movements
  • Muscle rigidity
  • Tremors
  • Weakness

Genetic tests can look for the defective gene that causes the disease. However, this test is not yet widely available. It is only found at certain research laboratories.

Tests such as MRI can help rule out other movement disorders and diseases.

Treatment of Hallervorden-Spatz disease

The goal of treatment is to control the symptoms. There is no specific treatment for Hallervorden-Spatz disease.

Prognosis (Outlook)

Hallervorden-Spatz gets worse and damages the nerves over time. It leads to a lack of movement and often death by early adulthood.

Potential Complications

Medication used to treat symptoms can cause complications. Being unable to move from the disease can lead to:

When to Contact a Health Professional

Call your health care provider if your child develops:

  • Increased stiffness in the arms or legs
  • Increasing problems at school
  • Unusual movements

Prevention of Hallervorden-Spatz disease

Genetic counseling is appropriate in families affected by this illness. There is no known way to prevent it.

Lang A. Other movement disorders. In: Goldman L, Ausiello D, eds. Cecil Medicine. 23rd ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 434.

Learn more about Hallervorden-Spatz disease

Review Date: 9/28/2010
Reviewed By: David C. Dugdale, III, MD, Professor of Medicine, Division of General Medicine, Department of Medicine, University of Washington School of Medicine; Daniel B. Hoch, PhD, MD, Assistant Professor of Neurology, Harvard Medical School, Department of Neurology, Massachusetts General Hospital. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.
Do not use this information for medical emergencies - Call 911. This information should not be used for the diagnosis or treatment of any medical condition. A licensed medical practitioner should always be consulted for diagnosis and treatment of any and all medical conditions. Links to other websites do not constitute endorsements and are provided for information only. Any duplication or distribution of this information is strictly prohibited.
Copyright 2011 A.D.A.M., Inc.
(web1)